Add BrightSurf on Google Email

National Comprehensive Cancer Network


Most non-English speakers in the U.S. are turned away before their first cancer visit according to new research in JNCCN

A new study from the University of Michigan found significant language-based disparities in patients' access to cancer care. English-speaking callers were able to get information on next steps 94% of the time, while Spanish-speakers and Mandarin-speakers were only connected at 38% and 28% respectively.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateSep 6, 2023

New study in JNCCN highlights rapid adoption of clinical research results into chemotherapy prescribing patterns

A new study published in JNCCN found that the adoption of clinical research results led to a significant increase in the use of shorter adjuvant chemotherapy periods, with CAPOX becoming more widely used. The study also revealed disparities in treatment patterns, with Black patients being more likely to receive shorter chemotherapy reg...

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateAug 7, 2023

New research in JNCCN finds telemedicine consistently outperforms in-person visits for cancer care when both are available

A large-scale study of patient experiences with telemedicine and in-person visits found that telemedicine consistently outperformed in-person visits in terms of access to care and provider engagement. The study analyzed survey responses from over 39,000 patients across more than 50,000 visits.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeSurvey·DateMay 8, 2023

New study in JNCCN identifies approach for improving end-of-life conversations for people with cancer

A new study published in JNCCN identifies a targeted approach to improve end-of-life conversations for people with cancer. Researchers found that specially trained oncology infusion room nurses can increase the rate of advance care planning, leading to more supported decision-making.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeRandomized controlled/clinical trial·DateApr 4, 2023

New research in JNCCN highlights the negative impact of continued exclusion of racial groups from research on cancer genomics

A recent study published in JNCCN found that the lack of genomic research for people with African ancestry is hindering efforts to reduce disparities in prostate cancer outcomes. The researchers evaluated molecular genetic results for 113 Black South African men diagnosed with advanced prostate cancer, identifying 17 pathogenic and pot...

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateMar 10, 2023

National Comprehensive Cancer Network updates annual conference with new in-person venue, hybrid format, expert-led sessions, highlighted research perspectives, and small-group conversations

The NCCN Annual Conference will debut a new hybrid format featuring in-person events at a new venue, allowing for hallway conversations and networking opportunities. The conference will also showcase more than 100 abstract poster presentations on various oncology-related categories.

Cancer symptom algorithm presented in JNCCN can aid doctors in predicting patients at risk for unplanned emergency visits

A new algorithm uses patient-reported outcomes to identify patients with cancer who are at increased odds of having unplanned emergency department visits. The algorithm, which calculates a symptom complexity score, has shown that patients with high complexity scores are three times more likely to use the ED.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateFeb 15, 2023

Surgery first for colon cancer? Not so fast, according to new study in JNCCN

Researchers discovered that pre-surgery immunotherapy significantly improved patient outcomes for locally advanced colorectal cancer. The treatment showed substantial longer survival benefits, including low recurrence rates, in patients with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) CRC.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateJan 11, 2023

Patients and doctors agree on treatment goals only half the time, according to JNCCN study on people with neuroendocrine tumors

A recent study by City of Hope found that only 30% of patients with advanced neuroendocrine tumors prioritize living longer as their top goal. Instead, 70% focus on addressing pain, fatigue, and losing function. The research highlights the need for better communication between care providers and patients to develop personalized treatme...

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateDec 12, 2022

Cancer patients treated with immunotherapy can safely receive mRNA COVID-19 vaccines, according to JNCCN study

Researchers analyzed 408 patients receiving immune checkpoint inhibitor therapy and found no increased risk of side effects from receiving both immunotherapy and the vaccine. The study supports NCCN's recommendations for COVID-19 vaccination in people with cancer, citing strong protection against severe COVID-19 for all variants.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateOct 17, 2022

New study in JNCCN suggests way to predict outcomes with high accuracy prior to surgery for pancreatic cancer patients

Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateSep 8, 2022

There’s a better way to detect high-risk medications in older adults with cancer according to new study in JNCCN

A new scale called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale was found to be more effective at predicting frailty than conventional methods. The scale identifies high-risk medications linked to falls and fatigue, allowing oncology teams to deprescribe them and improve patients' overall health.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateAug 10, 2022

Chemotherapy drugs from “rogue” online pharmacies could endanger leukemia patients, suggests research in JNCCN

A study found that a majority of online pharmacies selling imatinib, a chronic myeloid leukemia therapy, are uncertified and operate unsafely. Patients may face risks of nonadherence, treatment failures, and adverse events if they use these pharmacies.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeSystematic review·DateJul 28, 2022

JNCCN: Mismatch in breast cancer trial results and real-world outcomes based on treatment discontinuation

A population-based study found that patients with estrogen receptor-positive breast cancer who experienced hot flashes while on adjuvant hormone therapy had worse outcomes and a higher risk of early treatment discontinuation. The study suggests that managing side effects may not be enough to prevent treatment discontinuation, highlight...

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeData/statistical analysis·DateJun 21, 2022

New research in JNCCN encourages harnessing health technology to help cancer patients quit smoking

A new study published in the Journal of the National Comprehensive Cancer Network (JNCCN) found that incorporating the Electronic Health Record-Enabled Evidence-Based Smoking Cessation Treatment (ELEVATE) program into electronic health records can significantly improve smoking cessation rates among cancer patients. The research demonst...

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeData/statistical analysis·DateMay 11, 2022

NCCN pharmacy directors forum publishes recommendations for safely dispensing investigational medications for clinical trials

The National Comprehensive Cancer Network has published new consensus recommendations to improve the safety and efficiency of research studies involving investigational drugs. The recommendations focus on seven areas, including pharmacy workflows and collaboration with sponsors.

SourceNational Comprehensive Cancer Network·JournalAmerican Journal of Health-System Pharmacy·DateMar 15, 2022

New research in JNCCN raises concerns about clinical trial bias from undisclosed censoring

A recent study published in JNCCN found that 33 out of 81 studies lacked transparency on censoring, which can introduce bias and affect trial results. The researchers emphasize the need for improved transparency and reporting in clinical trials to ensure patients and clinicians make informed decisions.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateDec 15, 2021

New study in JNCCN finds disturbing lack of key leukemia medication

A recent study published in JNCCN found that only 31% of hospitals have immediate availability of all-trans retinoic acid (ATRA), a crucial blood cancer medication. This medication is essential for treating acute promyelocytic leukemia, which has a better prognosis when treated appropriately. The lack of ATRA availability poses a signi...

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeSurvey·DateNov 16, 2021

JNCCN: More people with cancer undergoing radiotherapy prefer telemedicine to in-person visits

A study published in JNCCN found that 45% of people with cancer prefer telemedicine over in-person visits, while general patient satisfaction scores are equally high. The research also revealed that patients preferred video conferencing over audio-only appointments and that telemedicine can reduce treatment-related costs.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeSurvey·DateOct 19, 2021

Are too many Phase III cancer clinical trials set up to fail?

A recent study published in JNCCN found that four out of five cancer therapies tested in Phase III trials did not achieve clinically-meaningful benefits in prolonging survival. The researchers analyzed 362 industry-sponsored trials and found that 87% were either false-positive or true-negative for meeting overall survival goals.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateSep 23, 2021

JNCCN study reveals neuroendocrine tumor mortality patterns to inform treatment decisions

A population-based cohort study in Canada identified mortality patterns for different types of neuroendocrine tumors (NETs), revealing varying risks of cancer-related and non-cancer death. The study found that small NETs can be safely monitored, while larger tumors may require more aggressive treatment.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeData/statistical analysis·DateAug 26, 2021

NCCN releases recommendations for standardizing quality measurement in oncology

The National Comprehensive Cancer Network (NCCN) has published a list of high-impact measures for assessing quality improvements in cancer care. The recommendations reflect a landscape analysis from leading oncology experts and include endorsement of 15 existing measures and seven new concepts proposed for development.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateMar 10, 2020